Chelsea have the chance to go top of the Premier League this evening as they host Leeds. Fans will return to Stamford Bridge for the first time since March for the clash, with 2,000 Blues supporters allowed in after London was placed in Tier 2 of the government’s coronavirus restrictions this week. Frank Lampard’s side currently sit two points behind both Tottenham and Liverpool, but with both sides not in action until Sunday they have the chance to reach the summit.
Follow The Independent for all the latest from the White House and beyond
Frank Lampard and Marcelo Bielsa will also resume their rivalry following ‘spygate’ with the Blues able to temporarily take top spot in the Premier League with victory
Military planes to fly vaccines in to Britain to avoid ports hit by Brexit. Officials fear delays even after EU deal as Boris Johnson and Ursula von der Leyen order talks to resume
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab (JNJ-64007957) for the treatment of relapsed or refractory multiple myeloma (MM). In heavily pretreated patients, the overall response rate (ORR) with teclistamab was 73 percent (16/22) at the recommended SC Phase 2 dose (RP2D).1 These results for the SC formulation support the recommended dose for the pivotal Phase 2 registration trial, which has started. In addition, updated results for the intravenous (IV) formulation demonstrate the durability of responses.1
For almost two decades the first week of December in Miami has been synonymous with artists, art fairs, champagne-soaked parties, pop up installations, an explosion of new graffiti, and traffic gridlock. After the coronavirus pandemic forced Art Basel Miami Beach to announce in September that it was canceling this year's fair, the galaxy of satellite fairs around the city followed suit. Art Basel is typically one of the busiest times for Miami, and the jolt could not have come at a worse time for this tourism-and-hospitality driven city hit hard by COVID-19.
PM to speak again with Ursula von der Leyen on Monday as wait for breakthrough continues
Romain Grosjean sat in a Haas Formula One car again on Saturday for the first time since escaping from a fiery crash with just burns to his hands during the Bahrain Grand Prix.
Thibault Giroud has perhaps been one of the most influential men in international rugby over the past 18 months, but he is also one of the least heralded. France's head of athletic performance has been a key figure in the country's rugby revolution of the past year, making a team that can - as the cliche has it - be somewhat laissez-faire when it comes to conditioning, one of the fittest on the planet. “France have never been fitter," says former flanker Serge Betsen. "He has been really important in what [coach] Fabien Galthie has done to change France. Before there was too much politics, but Galthie was allowed to bring in people like Giroud who we worked with at Toulon and who is trusted by everyone. "That is why France are achieving what they are - the right people are in the right jobs. And Giroud with such amazing experience - he is bringing in a lot of new ideas, which inspires the players.” Giroud's experience is obvious enough from just the quickest of glances at his LinkedIn page, although it is fair to say that he is possibly underselling himself. He mentions he was an Olympic athlete but not that he was a bronze medallist in bobsleigh at the 1998 Nagano Winter Games, nor that he was encouraged into that sport through a friendship with Prince Albert of Monaco. In the results-driven world of athletic performance, it is also curious that there is also no mention of how the 46-year-old was spotted in his youth by a scout from Dartmouth University in New Hampshire and took up an American Football scholarship. Giroud was a running back and was even drafted by the New York Jets, although he never played in the NFL. He did, however, have a career in NFL Europe and later briefly played rugby union, including the 2003-04 season as a wing at Saracens, a role he juggled with work as their conditioner.
Britain and European Union negotiators will meet in Brussels on Sunday in what the British team said was a final throw of the dice to clinch a post-Brexit trade deal. British Prime Minister Boris Johnson and European Commission President Ursula von der Leyen spoke on Saturday, and instructed their teams to resume the talks in a last ditch attempt to bridge significant differences. Both sides acknowledge that time is running out to strike a deal before a transition arrangement expires at the end of the year and sources gave a pessimistic readout after Johnson and von der Leyen spoke on Saturday.
President Donald Trump has fruitlessly pressed Georgia’s governor to call a special legislative session aimed at overturning the presidential election results in that state. Trump made his request iof Gov. Brian Kemp in a phone call on Saturday, and the governor refused. The call took place hours before Trump is to appear at a rally in Georgia, where Republicans hope he will dedicate his energy to imploring their supporters to vote in two runoff elections Jan. 5.
The call is just the latest in a series of brazen attempts to overturn the election result
She's one of this year's strongest dancers, but she hasn't scored a perfect 30 yet.
It's only been nearly 40 years!
The champions trailed twice before Muller’s late goal ensured they remain two points clear at the top of the Bundesliga
NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Intercept Pharmaceuticals Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT) from September 28, 2019, through October 7, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934. If you purchased Intercept securities, and/or would like to discuss your legal rights and options please visit Intercept Shareholder Lawsuit or contact Joseph R. Seidman Jr. toll free at (877) 779-1414 or Seidman@bernlieb.com.The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (ii) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.On May 22, 2020, Intercept reported that the FDA “has notified Intercept that its tentatively scheduled June 9, 2020 advisory committee meeting (AdCom) relating to the company’s [NDA] for [OCA] for the treatment of liver fibrosis due to [NASH] has been postponed” to “accommodate the review of additional data requested by the FDA that the company intends to submit within the next week.” On this news, Intercept’s stock price fell $11.18 per share, or 12.19%, to close at $80.51 per share on May 22, 2020.On June 29, 2020, Intercept issued a press release announcing that the FDA had issued a Complete Response Letter (“CRL”) rejecting the Company’s NDA for Ocaliva for the treatment of liver fibrosis due to NASH. According to that press release, “[t]he CRL indicated that, based on the data the FDA has reviewed to date,” the FDA “has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH.” The press release further advised, among other things, that the “[t]he FDA recommends that Intercept submit additional post-interim analysis efficacy and safety data from the ongoing REGENERATE study in support of potential accelerated approval and that the long-term outcomes phase of the study should continue.” On this news, Intercept’s stock price fell $30.79 per share, or 39.73%, to close at $46.70 per share on June 29, 2020.Then, on October 8, 2020, news outlets reported that Intercept was “facing an investigation from the [FDA] over the potential risk of liver injury in patients taking Ocaliva, [Intercept’s] treatment for primary biliary cholangitis, a rare, chronic liver disease.” On this news, Intercept’s stock price fell $3.30 per share, or 8.05%, to close at $37.69 per share on October 8, 2020.If you wish to serve as lead plaintiff, you must move the Court no later than January 4, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.If you purchased Intercept securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/interceptpharmaceuticalsinc-icpt-shareholder-class-action-lawsuit-stock-fraud-331/apply/ or contact Joseph R. Seidman Jr. toll free at (877) 779-1414 or Seidman@bernlieb.com.Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.Contact InformationJoseph R. Seidman, Jr. Bernstein Liebhard LLP https://www.bernlieb.com (877) 779-1414 Seidman@bernlieb.com
Obama: Democrats need 'universal language' to appeal to moderate votersFormer president says ‘if I spoke the language of James Baldwin on the stump … I’m probably not gonna to get a lot of votes in Iowa’
Signposts for single-family investors point south and west -- but there could be potential up north, too.
There are plenty of healthcare stocks that have seen share growth this year. Here are three lesser-known stocks that have the potential to continue that growth this month and beyond.
You'll never miss your flatscreen.